IRCT20200408046992N1招募中3 期
Evaluation of the Effect of Trifluoperazin in Treatment of Patients with Confirmed 2019 Novel Coronavirus(COVID- 19): An Open-Label Randomized Clinical Trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients with laboratory-confirmed COVID 19 infection with Real Time PCR and patients with evidence of lung involvement in CT Scan
- •Willing to provide informed consent
- •Age older than 12 years.
- •Patients admitted to specialized COVID-19 ward
- •Patients without Known severe allergy to trifluoperazine perazin and other phenothiazines such as cholorphenothiazines
- •Patients older than age 65 years are included if they do not suffer from Dementia-Related Psychosis
排除标准
- •Patient With a Liver Disorder
- •Patients with bacterial or viral infection
- •Pregnant women
- •Patients with benign prostatic hyperplasia (BPH)
- •Patients with intestinal obstruction
- •Patients with blood disorders or bone marrow failure
- •Coma patients and patients with central nervous system weakness
研究者
相似试验
招募中
2 期
Trifluoperazine Effectiveness in Treatment of CoronavirusCOVID-19.?????? ??? ?????J00-J99IRCT20200329046892N1Rasht University of Medical Sciences70
尚未招募
Unknown
A retrospective observational study of trifluridine tipiracil plus minus bevacizumab in pretreated mCRC patients with MSI-H MMR-D metastatic colorectal cancerJPRN-UMIN000051378The 22nd Century Cutting-Edge Medical Informaion Technology Organization15
尚未招募
不适用
Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000041621The 22nd Century Cutting-Edge Medical Informaion Technology Organization239
已完成
4 期
A clinical trial to study the effect of Triflusal in Aspirin resitant patientsCTRI/2011/04/001679Glenmark Pharmaceuticals Lts40
进行中（未招募）
1 期
Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a secondline therapy in patients with bile duct cancerPatients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment.EUCTR2018-002936-26-DEHeinrich-Heine-University Düsseldorf28